-
If you suspect exfoliative dermatitis caused by an adverse drug reaction to ustekinumab, stop treatment.
-
Measure serum immunoglobulin levels if recurrent infections develop. Consider bronchiectasis or pulmonary fibrosis if patients develop persistent respiratory symptoms.
-
Oral diclofenac is associated with a small increased risk of cardiovascular side effects and is therefore no longer available over the counter.
-
Aceclofenac is now contraindicated in patients with certain established cardiovascular diseases.
-
The new offence introduced in July does not apply in Northern Ireland nor replace any existing offences of driving.
-
From October 2014 Dexamethasone 4 mg/ml injection (Organon Laboratories Limited) will be replaced by Dexamethasone 3.8 mg/ml solution for injection (Aspen Pharma Trading Limited).
-
The Department for Transport has introduced a new offence of driving with certain controlled drugs above specified limits in the blood; this is likely to come into force on 2 March 2015.
-
We remind you to provide clear information to patients and caregivers regarding risk of accidental patch transfer and ingestion of patches, and need for appropriate disposal of patches.
-
Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
-
Restricted indication and new monitoring requirements.
-
Screening for hepatitis B virus is now recommended in all patients (not only those at risk of this infection) before starting treatment for all indications.
-
Public consultation launched on the continued availability of oral diclofenac as a pharmacy (P) medicine and on risk-minimisation measures advised by the Commission on Human Medicines.
-
Restricted dose and duration of use.
-
Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone.
Furthermore, a significant risk of se…
-
-
New recommendations after a Europe-wide review of cardiovascular safety.
-
Remember to report any suspected adverse reactions
-
Please be vigilant as life-threatening errors may occur
-
Rare cases of atypical femoral fracture with long-term use.
-
Safety review initiated following post-surgical fatalities in ultra-rapid metabolisers
-
Risk of serious skin-related adverse drug reactions, including Stevens-Johnson syndrome, occurring with carbamazepine may be increased in the presence of the HLA-A*3101 allele in patients of European descent or Japanese orig…
-
The non-identical nature of biological medicines and vaccines means it is very important that safety surveillance is carried out on a brand/product-specific basis.
-
Further evidence that the cardiovascular risk with diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors.
-
Fatal cases of severe symptomatic hypocalcaemia, and risk of hypocalcaemia at any time during treatment.
-
New simplified guidance on treating paracetamol overdose with intravenous acetylcysteine including an updated treatment nomogram.
-
Levofloxacin (a fluoroquinolone antibiotic) is unfavourable as first-line treatment for several indications.
-
Febuxostat must be stopped immediately if hypersensitivity occurs and must not be re-started in patients who have ever developed a hypersensitivity reaction to febuxostat.
-
Healthcare professionals are reminded that chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock.
-
Reminder that paediatric paracetamol liquids had been developed to ensure children receive optimum dosing for their age.
-
Supporting safer use
-
Updated dosing for paediatric paracetamol liquids has been developed to ensure children receive the optimum dose for their age.
-
A reminder to healthcare professionals to fill out Yellow Card reports.
-
Atypical femoral fractures reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis.
-
(Dextro)propoxyphene can have serious effects on the electrical activity of the heart (resulting in prolongation of the P-R and Q-T intervals, and widened QRS complexes), even at normal therapeutic doses.
-
Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.
-
European Medicines Agency says further measures should be put in place to minimise the risk of adverse skin reactions.
-
Risk of accidental overdose, particularly in infants and neonates.
-
A case of progressive multifocal leukoencephalopathy (PML) with a fatal outcome was reported in a patient with rheumatoid arthritis who had not previously received treatment with methotrexate or a TNF antagonist.
-
We continue to receive a substantial number of serious and fatal adverse event reports for warfarin through our Yellow Card Scheme.
-
Reminder on risk of serious and fatal toxicity in overdose.
-
All patients with cancer should have a dental check-up before bisphosphonate treatment.
-
The tighter controls being introduced to minimise risk of overuse and or addiction of painkillers containing codeine or dihydrocodeine.
-
Use of has led to serious paracetamol overdose in a 6-month-old infant.
-
A reminder for those who use topical ketoprofen to avoid direct sunlight, ultraviolet rays, sunbeds or sunlamps.
-
Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers.
-
How pharmacists can prevent counterfeits reaching patients.
-
Continued monitoring of medicines with a black triangle status.
-
You should take caution when you use NSAIDs in patients with renal impairment or are at risk.
-
Healthcare professionals may have more responsibility to accurately prescribe an unlicensed medicine or an off-label medicine than when they prescribe a medicine within the terms of its licence.
-
Spontaneous reporting on the Yellow Card portal has provided important information in the identification of PML associated with some drugs.